Needham & Company LLC Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $106.00

TransMedics Group (NASDAQ:TMDX) had its price target decreased by Needham & Company LLC from $142.00 to $106.00 in a report issued on Monday, Marketbeat reports. Needham & Company LLC currently has a buy rating on the stock.

Several other brokerages also recently weighed in on TMDX. Canaccord Genuity Group reiterated a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. UBS Group initiated coverage on TransMedics Group in a research report on Tuesday, July 28th. They set a “neutral” rating and a $80.00 target price on the stock. Finally, Weiss Ratings lowered TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and an average price target of $124.18.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $76.49 on Monday. The firm has a 50 day simple moving average of $73.14 and a 200-day simple moving average of $99.24. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The firm has a market cap of $2.64 billion, a PE ratio of 19.66 and a beta of 1.90. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 16.58%. The firm had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same period in the previous year, the company posted $0.92 EPS. The business’s quarterly revenue was up 20.7% on a year-over-year basis. On average, equities analysts expect that TransMedics Group will post 1.88 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Royal Bank of Canada grew its position in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of TransMedics Group by 13.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares in the last quarter. Finally, M&T Bank Corp purchased a new stake in shares of TransMedics Group during the 2nd quarter worth about $209,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Second-quarter revenue rose 20.7% year over year to approximately $190 million, exceeding analyst expectations. TransMedics also raised its fiscal 2026 revenue outlook to $737 million-$757 million, above the roughly $733.6 million consensus estimate. TransMedics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Piper Sandler reaffirmed its bullish view, maintaining an overweight rating and a $100 price target, implying substantial potential upside from recent levels. Piper Sandler Reaffirms TransMedics Rating
• Neutral Sentiment: Analyst sentiment remains mixed. UBS moved to a neutral rating and lowered its target to $77 from $80, while Piper Sandler retained a Buy rating despite reducing its target to $100 from $120. Analyst Ratings for TransMedics
• Negative Sentiment: Adjusted earnings were $0.44 per share, below the $0.50 consensus estimate and down from $0.92 a year earlier. Operating profit fell 35.1% and net income declined 57.9%, indicating that growth is not currently translating into comparable profit growth. TransMedics Earnings Miss Estimates
• Negative Sentiment: Investors are also concerned about contracting margins, sharply higher operating expenses, weaker operating cash flow, and rising liabilities. These factors overshadowed the revenue beat and raised questions about near-term execution. TransMedics Stock Dips After Earnings
• Negative Sentiment: Rosen Law Firm announced an investigation into potential fiduciary-duty breaches by TransMedics’ directors and officers, adding legal and reputational uncertainty. Reported insider activity also shows eight sales and no purchases over the past six months. Rosen Law Firm Investigation of TransMedics

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.